



Support to Research and Development at the International AIDS Vaccine Initiative (P161232)

OTHER | World | Health, Nutrition & Population Global Practice |
 Recipient Executed Activities | Investment Project Financing | FY 2017 | Seq No: 1 | ARCHIVED on 30-May-2017 | ISR27098 |

Implementing Agencies: International AIDS Vaccine Initiative, International AIDS Vaccine Initiative

Key Dates

Key Project Dates

Bank Approval Date:10-Feb-2017

Effectiveness Date:27-Feb-2017

Original Closing Date:30-Jun-2017

Revised Closing Date:30-Jun-2017

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

The Project Development Objective is to support the International AIDS Vaccine Initiative (IAVI) in the optimization and testing of one HIV vaccine candidate.

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components

Name

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	--	● Moderately Satisfactory
Overall Implementation Progress (IP)	--	● Moderately Satisfactory

Implementation Status and Key Decisions

Progress was made in developing six vector variants. Five variants (excluding the prototype) are currently in various stages of optimization.

Since preliminary data is very encouraging for one of the VSV variants, IAVI is moving forward with this construct while it continues to gather additional information. If promising, this variant will become the lead candidate for comparison to the prototype vaccine in the SHIV challenge model.

IAVI intends to generate and characterize the other variants in due course, to serve as backups or next-generation vaccines as needed.



IAVI is on track to initiate the NHP study in late June.

Key Decisions

To move progress ahead, IAVI has decided to increase its allocated resources in order to accelerate the laboratory testing of vaccine candidates. The Bank team's assessment, including assessment by independent product development consultants, is that the Project will achieve its objectives by the end of June.

Risks

Overall Risk Rating

Risk Category	Rating at Approval	Previous Rating	Current Rating
Overall	--	--	● Moderate

Comments

The overall rating is based on the following sub-ratings based on the PAD, which remain unchanged.

Research-related risks - High

Reputational risk - Moderate

Financing Arrangements - Medium to Low

Donors - Negligible

Bank Supervision and Implementation Capacity - Moderate

Results

Project Development Objective Indicators

▶A vector has been optimized (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	N	--	N	Y
Date	10-Feb-2017	--	13-Apr-2017	31-Mar-2017



Comments

The Project has not completed the optimization (generating, rescuing, and fully characterizing) of two lead candidates that would be used as comparison to the prototype vaccine VSVΔG-Env.BG505 in a macaque SHIV challenge study, which was anticipated to be completed by March 2017. However, it is anticipated that the two leading vectors would be fully characterized by the end of May and prepared for production and qualification in June, in time for the commencement of preclinical study in non-human primates (NHP) to test the vaccine candidates.

►Vector testing has been initiated (Yes/No, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	N	--	N	Y
Date	10-Feb-2017	--	13-Apr-2017	30-Jun-2017

Comments

With the primates now already in house awaiting to complete the quarantine requirement and the continuing promising data that is being gathered on the Env in position 1 construct, the Project is on track to initiate the NHP study in late June.

Overall Comments

Intermediate Results Indicators

►Five genetically modified VSVdG-Env.BG505 vaccines have been isolated and characteristics have been analyzed (Yes/No, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	N	--	N	Y
Date	10-Feb-2017	--	13-Apr-2017	01-Mar-2017



Comments

The delays were due to problems with (i) obtaining clones for the vectors; (ii) incorrect DNA templates from supplier; and (iii) staffing turnover.

► VSVdG-Env.BG505 mutants have been isolated after serial passage under conditions that select for viruses with increased replicative fitness. Mutant virus characteristics have been analyzed. (Yes/No, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	N	--	N	Y
Date	10-Feb-2017	--	13-Apr-2017	01-Mar-2017

Comments

The delays were due to problems with (i) obtaining clones for the vectors; (ii) incorrect DNA templates from supplier; and (iii) staffing turnover.

► A decision to test new VSVdG-Env.BG505 vaccines or revise a macaque study to evaluate the requirement for three doses have been made. (Yes/No, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	N	--	N	Y
Date	10-Feb-2017	--	13-Apr-2017	31-Mar-2017

Comments

IAVI anticipates to make a decision about testing new vaccine by the end of May 2017.



▶Candidate vaccines have been produced for a preclinical study. (Yes/No, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	N	--	N	Y
Date	10-Feb-2017	--	13-Apr-2017	01-Jun-2017

▶Preclinical study in non-human primates has been commenced. (Yes/No, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	N	--	N	Y
Date	10-Feb-2017	--	13-Apr-2017	30-Jun-2017

Overall Comments

Data on Financial Performance


Disbursements (by loan)

Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	Disbursed
P161232	TF-A4434	Effective	USD	1.80	1.80	0.00	1.80	0.00	100%

Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P161232	TF-A4434	Effective	08-Feb-2017	27-Feb-2017	27-Feb-2017	30-Jun-2017	30-Jun-2017

Cumulative Disbursements



Restructuring History

There has been no restructuring to date.

Related Project(s)

There are no related projects.